At 30 days, there were no deaths, strokes or re-hospitalizations. No patients had vascular complications, PVL (> moderate) or required a permanent pacemaker. Core lab echocardiographic data demonstrated a mean gradient of 6.3 mmHg, and valve area of 2.8 cm2 .

SENS-501, including the surgical delivery of the gene therapy, shows a good safety profile in all patients treated so far. 3 month results from a SENS-501 treated toddler in the first cohort demonstrate early promising hearing improvement. The second cohort assessing a higher dose of SENS-501 is ongoing and recruitment is close to being completed.

This FIH Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and the signs of early efficacy (LDL-C lowing effect, and liver fat quantitative value using MRI-PDFF) of PRD001 in adult healthy volunteers.

The study finds that CHAI (Computational Histology AI) biomarkers stratify recurrence and progression outcomes independently and outperform current guideline-based risk stratification

The study, titled “Augmented reality system for MRI-guided interventions: a cadaver study”, demonstrates the system’s potential to enhance MRI-guided needle procedures by improving procedural feasibility and reducing the need for repeated imaging scans.